Sk Biopharmaceuticals Co Ltd (326030) — Cash Flow Quality Index
Sk Biopharmaceuticals Co Ltd (326030) has a Cash Flow Quality Index of 0.17x as of March 2026. Operating cash flow of ₩17.92 Billion is below net income of ₩105.16 Billion, suggesting accrual-heavy earnings not yet converted to cash. Explore Sk Biopharmaceuticals Co Ltd cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Sk Biopharmaceuticals Co Ltd Cash Flow Quality Index (2021–2025)
Historical Cash Flow Quality Index for Sk Biopharmaceuticals Co Ltd across 3 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see how efficiently does Sk Biopharmaceuticals Co Ltd generate cash.
Annual Cash Flow Quality Index for Sk Biopharmaceuticals Co Ltd (2021–2025)
Year-by-year earnings quality comparison for Sk Biopharmaceuticals Co Ltd.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.66x | ₩176.33 Billion | ₩266.95 Billion | ▲ +67.6% |
| 2024 | 0.39x | ₩94.90 Billion | ₩240.74 Billion | ▲ +127.5% |
| 2021 | -1.43x | ₩-92.87 Billion | ₩64.85 Billion | — |